We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2024
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Protocol Enables DNA Sequencing from Small or Degraded RNA Samples

By LabMedica International staff writers
Posted on 18 Apr 2011
A company with expertise in DNA and RNA sample preparation has joined forces with a major manufacturer of DNA sequencing equipment to develop a unique sample preparation method and high-throughput sequencing solution for small and degraded RNA samples.

454 Life Sciences (Branford, CT, USA), a subsidiary of Roche (Basel, Switzerland), and NuGEN Technologies (San Carlos, CA, USA) have developed a solution to the problem of working with limited amounts of sample material using both NuGEN's proprietary isothermal linear amplification (SPIA) products and the GS FLX Titanium cDNA Rapid Library Preparation protocol for the 454 GS Junior and GS FLX Systems for DNA sequencing.

Image: The 454 GS Junior system for DNA sequencing (Photo courtesy of Roche).
Image: The 454 GS Junior system for DNA sequencing (Photo courtesy of Roche).

"NuGEN's innovative sample preparation solutions provide a unique and powerful tool which will enable researchers to obtain high-quality data from their less abundant samples,” said Elizabeth Hutt, CEO of NuGEN Technologies. "Together with 454 Sequencing Systems, the research community can perform whole transcriptome profiling on samples with as little as 500 pg of total RNA. Being able to collaborate with a leading NGS platform provider such as Roche, enables customers to leverage NuGEN's linear amplification technology while obtaining long and highly accurate sequence reads.”

"We are sensitive to the challenges many researchers face when working with precious and often irreplaceable samples,” said Dr. Todd E. Arnold, vice president of development at 454 Life Sciences. "By combining NuGEN's amplification technology with 454 Sequencing Systems, we provide a solution that meets these researchers' needs, while allowing them to leverage the power of 454 Sequencing System's long read lengths, which are critical for both de novo transcriptome assembly and comprehensive identification of splice variants and fusion transcripts.”

Related Links:
454 Life Sciences
Roche
NuGEN Technologies



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Automated Nucleic Acid Extractor
eLab
New
Serum Toxicology Benzodiazepine Assay
DRI Serum Toxicology Benzodiazepine Assay

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries